Skip to main content
AmigoFish

GLP-1 targets beyond obesity, and misusing brain data

From Science Magazine Podcast · · 46 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

First up on the podcast, people are buying consumer-grade brain wave detectors ostensibly to help with sleep, concentration, and meditation. But as freelance investigative journalist Jonathan Moens (https://jonathan-moens.com/) describes, companies are getting more than the price of the devices in the exchange (https://www.science.org/doi/10.1126/science.zp18ht9)—including training data for artificial intelligence models—in many cases without the consent of the user.

Next on the show, we delve into the many uses for glucagonlike peptide-1 (GLP-1) agonist drugs beyond reducing obesity. Host Sarah Crespi talks with one of the special issue editors, Yevgeniya Nusinovich, senior editor at Science, about their potential for everything from improving cognition to combating cancer. Then we hear from Nora Volkow (https://nida.nih.gov/about-nida/directors-page/biography-dr-nora-volkow), director of the National Institute on Drug Abuse at the National Institutes of Health, about hopes for using GLP-1 therapies to address addiction (https://www.science.org/doi/10.1126/science.aej9836) to a range of substances.

See the whole special issue here (https://www.science.org/doi/10.1126/science.aen0869).

This week’s episode was produced with help from Podigy (https://podigy.co/).

Image: Long Wei/VCG via Getty Images

Learn more about your ad choices. Visit megaphone.fm/adchoices (https://megaphone.fm/adchoices)

Back to Science Magazine Podcast · Report a problem